# Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

> **NCT03070093** · — · APPROVED_FOR_MARKETING · sponsor: **Astellas Pharma Global Development, Inc.**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- FMS-like Tyrosine Kinase-3 (FLT3) Mutations

## Interventions

- **DRUG:** gilteritinib

## Key facts

- **NCT ID:** NCT03070093
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070093, "Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03070093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*